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Abstract Vitamin B12 deficiency impairs DNA synthesis
and causes erythroblast apoptosis, resulting in anaemia
from ineffective erythropoiesis. Iron and cobalamin defi-
ciency are found together in patients for various reasons.
We have observed that cobalamin deficiency masks iron
deficiency in some patients. We hypothesised that iron is
not used by erythroblasts because of ineffective erythro-
poiesis due to cobalamin deficiency. Therefore, we aimed
to demonstrate that depleted iron body reserves are masked
by cobalamin deficiency. Seventy-five patients who were
diagnosed with cobalamin deficiency were enrolled in this
study. Complete blood counts and serum levels of iron,
unsaturated iron binding capacity (UIBC), ferritin, vitamin
B12, and thyroid stimulant hormone were determined at
diagnosis and after cobalamin therapy. Patients who had a
combined deficiency at diagnosis and after cobalamin
therapy were recorded. Before cobalamin therapy, we
found increased serum iron levels (126.4 ± 63.4 lg/dL),
decreased serum UIBC levels (143.7 ± 70.8 lg/dL),
increased serum ferritin levels (192.5 ± 116.4 ng/mL), and
increased transferrin saturation values (47.2 ± 23.5 %).
After cobalamin therapy, serum iron levels (59.1 ± 30 lg/
dL), serum ferritin levels (44.9 ± 38.9 ng/mL) and trans-
ferrin saturation values (17.5 ± 9.6 %) decreased, and
serum UIBC levels (295.9 ± 80.6 lg/dL) increased. Sig-
nificant differences were observed in all values
(p \ 0.0001). Seven patients (9.3 %) had iron deficiency
before cobalamin therapy, 37 (49.3 %) had iron deficiency
after cobalamin therapy, and a significant difference was
detected between the proportions of patients who had iron
deficiency (p \ 0.0001). This study is important because
insufficient data are available on this condition. Our results
indicate that iron deficiency is common in patients with
cobalamin deficiency, and that cobalamin deficiency can
mask iron deficiency. Therefore, we suggest that all
patients diagnosed with cobalamin deficiency should be
screened for iron deficiency, particularly after cobalamin
therapy.
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Introduction
Deficiencies in a number of vitamins and minerals required
for normal erythropoiesis (haematinics) is associated with
anaemia [1]. Vitamin B12 and folate (the most common
haematinics) are the most prevalent forms of vitamin
deficiency worldwide [1], and vitamin B12 deficiency is a
major public health problem [2]. Deficiency of folate or
cobalamin causes megaloblastic anaemia, a disease in
which pancytopenia results from differentiating haemato-
poietic cells that die before reaching maturity [3]. This
effect is most prominent in the erythroid lineage and is
termed ineffective erythropoiesis [3].
A lack of vitamin B12 may be caused by insufficient
intake or malabsorption of the vitamin [2]. Insufficient
intake of vitamin B12 is seen in vegetarians and vegans [2].
Malabsorption of vitamin B12 occurs in patients suffering
from a number of gastrointestinal conditions [2]. Common
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conditions are related to decreased or abolished output of
gastric intrinsic factor and/or hypo- and achlorhydria, as
seen in patients with destroyed gastric mucosa caused
either by an autoimmune mechanism or by gastric atrophy
[2]. Importantly, a recent study suggested that vitamin B12
deficiency may be preceded by iron deficiency in these
cases [2], and impaired iron absorption is a likely conse-
quence [4]. However, screening and preventive measures
for iron deficiency are commonly overlooked [4], and cli-
nicians must be aware of coexisting conditions, particularly
iron deficiency [5].
Based on our clinical observations and the few data
about the association between cobalamin and iron defi-
ciency, we hypothesised that cobalamin deficiency masks
iron deficiency because of decreased iron utilisation in
erythroid cells depending on slowed erythropoiesis.
Therefore, we aimed to demonstrate that depleted iron
body reserves could be masked depending on ineffective
erythropoiesis in patients with cobalamin deficiency.
Methods
Patients
This study was a retrospective, cross-sectional, single
centre study. Seventy-five patients diagnosed with cobal-
amin deficiency between January 2005 and November
2013 were enrolled. The selection of patients was labora-
tory based, and independent from aetiology. Patients who
had folate deficiency and hypothyroidism were excluded.
Measurements
Complete blood counts and serum iron, unsaturated iron
binding capacity (UIBC), ferritin, vitamin B12, and thyroid
stimulant hormone (TSH) levels were determined at diag-
nosis and after cobalamin therapy. Iron indices were
assessed when vitamin B12 deficiency findings disappeared
(generally 1–3 months after initiating cyanocobalamin
therapy).
Serum vitamin B12 and TSH concentrations were mea-
sured using an electrochemiluminesce-immunoassay tech-
nique intended for use with the Elecsys reagent kit supplied
by Roche Diagnostics GmbH (Mannheim, Germany), and
run on Cobas e 601 immunoassay analyser (Roche Diag-
nostics). Serum iron and UIBC were measured by the
ferrozine method (Roche Diagnostics), and serum ferritin
was measured by an immunoturbidimetric method (Roche
Diagnostics) and run on a Cobas e 601 immunoassay
analyser. Transferrin saturation was calculated as the ratio
of serum iron to total iron binding capacity 9 100. Com-
plete blood counts of all patients were analysed with a
Coulter LH 750 haematological analyser (Beckman-Coul-
ter, Brea, CA, USA).
Definitions
Cobalamin deficiency was defined as serum cobalamin
level \100 pg/mL with macrocytosis [6], and iron defi-
ciency was defined as a serum ferritin level \15 ng/mL
and/or transferrin saturation\16 % according to the World
Health Organisation criteria.
Treatments
Cyanocobalamin was used to treat vitamin B12 deficiency
in all patients. Patients received 1,000 lg vitamin B12
intramuscularly daily for 7 days, then 1,000 lg weekly for
4 weeks, and 1,000 lg every month for maintenance
therapy.
Statistical Analysis
Patient characteristics were examined using descriptive sta-
tistics. Continuous variables are presented as mean ± stan-
dard deviation (SD), and categorical variables are defined as
percentages. The Chi square and t-tests were used to compare
proportions and means for categorical and continuous vari-
ables, respectively. Variables with significant p values
(p \ 0.05) and marginally insignificant p values (p \ 0.1) in a
univariate analysis were included in a multivariate analysis.
All significance tests were two-tailed. SPSS 17.0 for Windows
statistical software (SPSS Inc., Chicago, IL, USA) was used
for all statistical calculations.
Results
The study included 75 patients [37 (49.3 %) females and
38 (50.7 %) males; mean age, 64.3 ± 14.4 years;
65.5 ± 15.6 years for females and 63.1 ± 13.3 years for
males]. The characteristics of the patients at diagnosis, and
after cobalamin treatment, and comparisons between the
groups are shown in Table 1.
Seven patients (9.3 %) in 75 patients had iron deficiency
before cobalamin therapy, 37 patients (49.3 %) in 75
patients had iron deficiency after cobalamin therapy, and a
significant difference was detected between the proportion
of patients who had iron deficiency (p \ 0.0001).
The characteristics of the 38 patients who had pure
cobalamin deficiency at diagnosis and after cobalamin
treatment and a comparison between the groups are shown
in Table 2.
The characteristics of the 37 patients who had both iron
and cobalamin deficiency at diagnosis, and after the
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cobalamin treatment, and a comparison between the groups
are shown in Table 3.
Between patients who had pure cobalamin deficiency
and combine deficiency, there were significant differences
in serum UIBC (p = 0.048), ferritin (p = 0.013), red blood
cells (RBCs) (p = 0.023), haematocrit (p = 0.049), and
mean corpuscular volume (MCV) values (p = 0.044)
before cobalamin therapy, and in serum iron (p \ 0.0001),
UIBC (p \ 0.0001), ferritin (p = 0.001), TSH
(p \ 0.0001) and MCV values (p = 0.029) after cobalamin
therapy. There was no significant difference in RDW
before and after cobalamin therapy (p = 0.575 and
p = 0.131, respectively).
Discussion
Folate, vitamin B12, and iron have crucial roles in eryth-
ropoiesis [7]. Erythroblasts require folate and vitamin B12
for proliferation during differentiation [7]. A deficiency of
folate or vitamin B12 inhibits purine and tymidylate syn-
thesis, impairs DNA synthesis, and causes erythroblast
apoptosis, resulting in anaemia from ineffective erythro-
poiesis. Erythroblasts require large amounts of iron for
haemoglobin synthesis [7].
Iron and cobalamin deficiency can be found together in
patients depending on various reasons [2, 4, 5, 8, 9]. In our
study 37 (49.3 %) of the 75 patients had an iron deficiency
after cobalamin therapy. Interestingly, we detected only
seven patients (9.3 %) with iron deficiency before cobal-
amin therapy. Cobalamin deficiency complicates the
diagnosis of iron deficiency. Similarly, Atrah and Davidson
[4] reported that iron deficiency is a common complication
in patients with long-standing pernicious anaemia and that
its diagnosis and treatment are commonly neglected.
Demirog˘lu and Du¨ndar [8] found that iron deficiency
commonly accompanies patients with pernicious anaemia
and that this is more pronounced in elderly patients.
We hypothesised that iron is not used by erythroblasts
because of ineffective erythropoiesis due to cobalamin defi-
ciency. Although an iron deficiency existed in the patients, it
is found that serum iron indices were high. Our findings
Table 2 Baseline and after cobalamin treatment data of the 38
patients who had pure cobalamin deficiency
Baseline
(mean ± SD)
After
treatment
(mean ± SD)
p values
WBC (9 103/lL) 4.8 ± 1.4 7.9 ± 3.3 \0.0001
RBC (9 1012/L) 2.15 ± 0.68 4.61 ± 0.64 \0.0001
Hb (g/dL) 8.9 ± 2.7 14.1 ± 1.7 \0.0001
Hct (%) 26.0 ± 7.8 42.0 ± 5.1 \0.0001
MCV (fL) 121.2 ± 7.2 91.6 ± 6.3 \0.0001
RDW (%) 20.2 ± 4.9 15.6 ± 2.7 0.001
PLT (9 109/L) 163 ± 69 225 ± 65 0.001
Vitamin B12 (pg/mL) 58.9 ± 18.0 –
TSH (lIU/mL) 2.04 ± 1.35 –
Serum iron (lg/dL) 123.1 ± 56.4 77.8 ± 27.5 0.008
Serum UIBC (lg/dL) 124.8 ± 63.0 244.1 ± 61.6 \0.0001
Serum ferritin (ng/mL) 208.3 ± 101.3 64.3 ± 35.3 \0.0001
Transferrin saturation
(%)
50.4 ± 24.1 24.3 ± 8.1 \0.0001
Table 3 Baseline and after cobalamin treatment data of the 37
patients who had both iron and cobalamin deficiency
Baseline
(mean ± SD)
After
treatment
(mean ± SD)
Sig.
(p values)
WBC (9 103/lL) 5.5 ± 2.0 7.9 ± 2.3 \0.0001
RBC (9 1012/L) 2.65 ± 0.68 4.72 ± 0.68 \0.0001
Hb (g/dL) 10.5 ± 2.5 13.2 ± 1.8 \0.0001
Hct (%) 30.7 ± 7.4 40.1 ± 4.8 \0.0001
MCV (fL) 116.7 ± 6.9 85.8 ± 9.9 \0.0001
RDW (%) 19.4 ± 4.0 17.1 ± 3.5 0.047
PLT (9 109/L) 193 ± 72 251 ± 54 \0.0001
Vitamin B12 (pg/mL) 59.3 ± 15.0 –
TSH (lIU/mL) 2.58 ± 1.95 –
Serum iron (lg/dL) 112.0 ± 66.9 40.5 ± 19.0 \0.0001
Serum UIBC (lg/dL) 164.7 ± 64.0 347.7 ± 62.3 \0.0001
Serum ferritin (ng/mL) 124.3 ± 107.3 25.6 ± 32.9 \0.0001
Transferrin saturation
(%)
39.8 ± 22.5 10.7 ± 5.0 \0.0001
Table 1 Data of all the 75 patients at baseline and after cobalamin
treatment
Baseline
(mean ± SD)
After
treatment
(mean ± SD)
p values
WBC (9 103/lL) 5.2 ± 1.9 7.9 ± 2.8 \0.0001
RBC (9 1012/L) 2.29 ± 0.69 4.67 ± 0.65 \0.0001
Hb (g/dL) 9.3 ± 2.5 13.6 ± 1.8 \0.0001
Hct (%) 27.1 ± 7.6 41.1 ± 5.0 \0.0001
MCV (fL) 119.3 ± 8.3 88.7 ± 8.7 \0.0001
RDW (%) 20.2 ± 4.6 16.4 ± 3.2 \0.0001
PLT (9 109/L) 167 ± 68 238 ± 60 \0.0001
Vitamin B12 (pg/mL) 56.9 ± 17.8 –
TSH (lIU/mL) 2.46 ± 2.32 –
Serum iron (lg/dL) 126.4 ± 63.4 59.1 ± 30.0 \0.0001
Serum UIBC (lg/dL) 143.7 ± 70.8 295.9 ± 80.6 \0.0001
Serum ferritin (ng/mL) 192.5 ± 116.4 44.9 ± 38.9 \0.0001
Transferrin saturation
(%)
47.2 ± 23.5 17.5 ± 9.6 \0.0001
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support this notion, as 37 patients had a combined deficiency
before cobalamin therapy. After cobalamin therapy, when
ineffective erythropoiesis disappeared, serum iron levels
decreased to 40.5 lg/dL, UIBC levels increased to 347.7 lg/
dL, serum ferritin levels decreased to 25.6 ng/mL, and serum
transferrin saturation levels decreased to 10.7 % in 37 patients
who had both iron and cobalamin deficiency (Table 3).
Similarly, Hillman et al. [11]. also demonstrated that
patients with pernicious anaemia prior to vitamin B12
therapy show very poor Fe59 utilisation, and that Fe59
utilisation increases after vitamin B12 therapy. Gafter-Gvili
et al. [12]. reported that abnormalities in iron metabolism
associated with megaloblastic anaemia rapidly reverse
following vitamin B12 therapy in patients with pernicious
anaemia. Bessman [10] reported seven patients who had
vitamin deficiencies, four with B12, two with folate, and
one with both. The serum transferrin saturation of these
patients at admission was elevated; however, after initial
vitamin therapy without iron, transferrin saturation was
\15 % in four, and bone marrow in all cases was mega-
loblastic with increased iron stores on admission [10].
Additionally, Remacha et al. [13]. reported that serum
erythropoietin levels were inappropriately low for the degree
of anaemia in patients with vitamin B12 deficiency compared
with those with a pure iron deficiency. According to the results
of our study, serum UIBC, ferritin, and MCV levels may be
useful for diagnosing an iron deficiency in patients with a
combined deficiency before cobalamin therapy, but we did
not find a significant index that would help differentially
diagnose a pure cobalamin deficiency and a combined defi-
ciency before cobalamin therapy. As expected, we found that
all iron indices were useful for diagnosing iron deficiency
after cobalamin therapy. It is probably that iron deficiency
emerges as obvious when normal erythropoiesis begin to
instead of ineffective erythropoiesis and increase iron util-
isation with cobalamin therapy.
Based on these findings, we think that decreased iron
utilization of erythroid cells depending on various factors
(e.g. ineffective erythropoiesis and inappropriate secretion
of erythropoietin) in cobalamin deficiency mask iron defi-
ciency. It is likely that increased iron utilization in bone
marrow after cobalamin administration exposes iron defi-
ciency, when normal erythropoiesis begins to instead of
ineffective erythropoiesis.
Study Limitations
Despite its contribution to the literature, this study has some
limitations. The retrospective nature of the study design pre-
vented determination of blood picture findings of patients. It is
expected that combine deficiency have dimorphic blood pic-
ture before treatment. Unfortunately, it could not be evaluated
because of our study was retrospective and data could not be
reached. Secondly, bone marrow findings and status of
erythropoiesis was not determined.
Conclusion
The study is important because insufficient data are avail-
able on this condition. Our results indicate that iron defi-
ciency is common in patients with cobalamin deficiency,
and we suspect that many clinicians may overlook devel-
oped iron deficiency after cobalamin therapy. Therefore,
we suggest that all patients diagnosed with cobalamin
deficiency should be screened for iron deficiency, partic-
ularly after cobalamin therapy.
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